New Therapeutic Strategy Targets Drug-Resistant Triple-Negative Breast Cancer

Researchers at Baylor College of Medicine have discovered a critical vulnerability in triple-negative breast cancers (TNBC) that develop resistance to chemotherapy due to loss of the LIG1 gene. By identifying the underlying molecular mechanisms of platinum resistance, the team developed drug combinations using available medications to reduce tumor growth in animal models. This breakthrough is particularly significant for patients with TNBC and TP53 mutations, a particularly aggressive form of breast cancer. The findings highlight LIG1 status as an important factor for identifying which patients may benefit from specific treatment strategies in current and future clinical trials. This research, published in Molecular Cancer Therapeutics, offers new hope for improving outcomes in this challenging cancer type.